Pimavanserin
Authors:
- 1 April 2017
- journal article
- review article
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 7 (2) , 157-162
Abstract
Purpose of review: In April 2016, the Food and Drug Administration (FDA) approved a first-in-class atypical antipsychotic medication called pimavanserin for the treatment of Parkinson disease psychosis (PDP). We aim to inform readers about its indications, effectiveness, and safety profile. Recent findings: Pimavanserin acts as an inverse agonist at serotonin 5-HT2A receptors and has negligible effects on other receptors, thereby avoiding the D2 receptor antagonism that can potentially worsen motor symptoms. Its FDA approval was based primarily on the results of a single randomized, placebo-controlled phase 3 trial. Summary: While pimavanserin appears to be a safe, effective, and well-tolerated therapeutic option for PDP, additional clinical trials and open-label extension studies are needed to determine the long-term safety and efficacy of this promising therapy. In the meantime, prescribers need to be aware of the possible adverse effects of pimavanserin including QT interval prolongation and a potential to cause a paradoxical worsening of symptoms.Keywords
This publication has 23 references indexed in Scilit:
- Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease PsychosisArchives of Neurology, 2011
- Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinationsMovement Disorders, 2010
- Changes on 5-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson's disease modelPhysiology & Behavior, 2007
- Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work groupMovement Disorders, 2007
- Rater-blinded, Prospective ComparisonClinical Neuropharmacology, 2006
- Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's diseaseMovement Disorders, 2006
- Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2 R,3 R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse AgonistThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Donepezil in the treatment of hallucinations and delusions in Parkinson’s diseaseNeurological Sciences, 2002
- Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's DiseaseNew England Journal of Medicine, 1999
- Plasma Clozapine Levels and the Treatment of L-DOPA-Induced Psychosis in Parkinson's Disease A High Potency Effect of ClozapineNeuropsychopharmacology, 1995